Literature DB >> 11224275

Serotonin involvement in the discriminative stimulus effects of mu and kappa opioids in rats.

K.R. Powell1, M.J. Picker, L.A. Dykstra.   

Abstract

The role of serotonin (5-HT) in the discriminative stimulus effects of opioids was examined using a two-lever, food-reinforced drug discrimination procedure. The effects of the 5-HT(1A) full agonist 8-OH-DPAT, the 5-HT(1A) partial agonist buspirone and the 5-HT(2) antagonist ketanserin were evaluated in rats trained to discriminate the mu opioid agonist morphine, or the kappa opioid agonist U50, 488 from saline. In rats trained to discriminate 5.6mg/kg of morphine from saline, morphine dose-dependently substituted (produced >/= 80% morphine-appropriate responding) for the morphine stimulus. In contrast, U50,488, 8-OH-DPAT and ketanserin did not substitute for morphine, and buspirone produced only a small degree of substitution (approx. 40% morphine-appropriate responding). When administered in combination with morphine, 8-OH-DPAT, but not buspirone and ketanserin, attenuated the discriminative stimulus effects of higher doses of morphine. In rats trained to discriminate 5.6mg/kg of U50, 488 from saline, U50, 488 dose-dependently substituted for the U50, 488 stimulus. When administered alone, 8-OH-DPAT and buspirone partially substituted (produced between 40% and 79% U50, 488-appropriate responding) for the U50,488 stimulus, whereas morphine and ketanserin did not substitute for U50,488. The opioid antagonist naltrexone failed to antagonize the effects of 8-OH-DPAT and buspirone suggesting that the effects of these drugs in U50,488-trained rats were not mediated by opioid receptors. When administered in combination with U50,488, 8-OH-DPAT, but not buspirone or ketanserin, attenuated the discriminative stimulus effects of the training dose of U50,488. These results suggest that the 5-HT system is involved in the discriminative stimulus effects of both morphine and U50,488, although the exact nature of this 5-HT involvement is not clear.

Entities:  

Year:  1994        PMID: 11224275

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  8 in total

1.  Discriminative stimulus effects of serotonin agonists, neutral antagonists, and inverse agonists in pigeons: perspectives on intrinsic efficacy measurements in vivo.

Authors:  Martilias Farrell; Sharon Rosenzweig-Lipson; Ellen Walker
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

2.  The contribution of serotonin 1A receptors to kappa opioid immunosuppression.

Authors:  M A Cheido; G V Idova
Journal:  Neurosci Behav Physiol       Date:  2009-06-11

3.  Discriminative stimulus effects of the 5HT1A agonist 8-OH-DPAT: attenuation by mu but not by kappa opioids.

Authors:  D Morgan; M J Picker
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

4.  Opiate states of memory: receptor mechanisms.

Authors:  L A Bruins Slot; F C Colpaert
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

5.  Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms.

Authors:  Daniela Rüedi-Bettschen; James K Rowlett; Roger D Spealman; Donna M Platt
Journal:  Psychopharmacology (Berl)       Date:  2009-10-27       Impact factor: 4.530

6.  Depletion of serotonin decreases the effects of the kappa-opioid receptor agonist U-69593 on cocaine-stimulated activity.

Authors:  Elena Zakharova; Stephanie L Collins; Maria Aberg; Adarsh Kumar; J B Fernandez; Sari Izenwasser
Journal:  Eur J Pharmacol       Date:  2008-02-29       Impact factor: 4.432

Review 7.  Kappa Opioid Receptor Mediated Differential Regulation of Serotonin and Dopamine Transporters in Mood and Substance Use Disorder.

Authors:  Durairaj Ragu Varman; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  Handb Exp Pharmacol       Date:  2022

Review 8.  Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges.

Authors:  Ewa Galaj; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neurosci Biobehav Rev       Date:  2020-05-03       Impact factor: 8.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.